Merck VP & Chief Licensing Officer Barbara Yanni: An Interview With “The Pink Sheet” DAILY
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck is bolstering its pipeline through acquisitions and licensing deals, many in biotech. The drug maker evaluates 6,000 opportunities per year and signed 44 transactions in 2005.
You may also be interested in...
Merck Finds Licensing More Palatable Than Large Acquisitions
During BIO-Europe panel, AstraZeneca exec says firm’s $15.6 billion acquisition of MedImmune gives it major inroads into biologics.
Merck Finds Licensing More Palatable Than Large Acquisitions
During BIO-Europe panel, AstraZeneca exec says firm’s $15.6 billion acquisition of MedImmune gives it major inroads into biologics.
Big Pharma Is Paying More, Earlier For Biotechs
Acquisition deals become more expensive as pharmas compete to fill pipelines, execs say at BIO meeting in Boston.